Barcelona osteoarthritis foundation connecting joint disease expertise to metabolomics research and 3D bioprinted tissue regeneration.
The Osteoarthritis Foundation International (OAFI) is a Barcelona-based patient-focused research foundation dedicated to musculoskeletal diseases, with a core clinical focus on osteoarthritis and joint disorders. In EU research projects, they provide disease-specific biological knowledge, patient community access, and clinical endpoint grounding — connecting laboratory science to real-world joint pathology. In PREVENTOMICS they contributed expertise in metabolic and inflammatory biomarkers relevant to diet-related disease; in TRiAnkle they bring deep knowledge of joint tissue biology, osteochondral injury, and the clinical requirements for ankle joint repair. They are not a wet-lab institution — they are a disease authority that makes biomedical and engineering research clinically credible and patient-relevant.
Both PREVENTOMICS and TRiAnkle address joint-related pathology — metabolic contributors to joint disease in the first, and direct tissue regeneration of ankle osteochondral injuries in the second.
PREVENTOMICS focused on omics sciences, metabolomics, and biomarkers to track metabolism deregulation and support personalized dietary interventions for diet-related diseases.
TRiAnkle targets 3D bioprinted collagen and gelatine scaffolds with nanoencapsulation and growth factor delivery for tissue regeneration of the ankle joint.
PREVENTOMICS built decision support systems to generate personalized meal recommendations based on individual metabolic and genomic profiles.
From 2018, OAFI was active in data-driven preventive medicine: omics, metabolomics, and digital decision tools for diet-related disease prevention. By 2021 their focus shifted sharply toward physical tissue repair — 3D bioprinting, collagen scaffolds, nanoencapsulation, and bioreactor-based engineering for ankle and joint injuries. The thread connecting both phases is joint disease itself: metabolic and dietary contributors in the early period, structural and regenerative intervention more recently.
OAFI is moving toward regenerative medicine and advanced biomaterials for joint repair, making them an increasingly relevant partner for projects at the intersection of biofabrication, nanotechnology, and musculoskeletal clinical application.
OAFI participates exclusively as a consortium partner — they have never led an H2020 project. Across two projects they have engaged with 36 unique partners in 9 countries, indicating they join large, multi-stakeholder consortia where they contribute specialized disease knowledge rather than leading technical development. This profile makes them a practical specialist contributor: valuable for adding clinical legitimacy and patient-focused grounding, but not typically responsible for project coordination or management.
OAFI has collaborated with 36 unique partners across 9 countries through just 2 projects, indicating consistent participation in large, internationally distributed consortia. Their network likely spans universities, biotech companies, and clinical institutions across multiple European countries.
As a disease foundation rather than a university or hospital, OAFI brings something most technical partners cannot: disease advocacy expertise, patient community access, and a clear clinical endpoint perspective specifically around osteoarthritis and joint disorders. They fill the disease authority role in a consortium — validating that the research addresses a genuine clinical need and helping translate findings into patient impact. For any project touching joint biology, musculoskeletal health, or biomaterials for orthopedic application, they add clinical credibility that engineering-heavy consortia often lack.
